• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

五个欧洲国家非椎体骨质疏松性骨折相关直接单位成本的估算。

Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries.

作者信息

Bouee S, Lafuma A, Fagnani F, Meunier P J, Reginster J Y

机构信息

CEMKA, 43 boulevard du Maréchal Joffre, 92340 Bourg La Reine, France.

出版信息

Rheumatol Int. 2006 Oct;26(12):1063-72. doi: 10.1007/s00296-006-0180-x. Epub 2006 Sep 5.

DOI:10.1007/s00296-006-0180-x
PMID:16953395
Abstract

The objective of this study was to estimate the unit costs of non-vertebral osteoporotic fractures in five European countries based on the results of the SOTI and TROPOS clinical trials in postmenopausal osteoporotic women. The information recorded in the Case Report Forms was used. The perspective of third party payers was adopted. Hip fracture unit cost was the highest. The ranges of costs among countries was narrow for hip from 8,346 euros (Italy) to 9,907euros (France), but wider for other fractures: 890 euros (Spain) to 2,022 euros (Italy) for wrist, 1,167euros (Spain) to 3,268 euros (Italy) for pelvis, 837euros (Spain) to 2,116 euros (Italy) for sternum/clavicle, 565 euros (Spain) to 908 euros (France) for rib, 1,518 euros (Spain) to 3,651 euros (Belgium) for humerus, 1,805 euros (Spain) to 3,521 euros (Italy) for leg. The costs of those fractures should be considered when estimating the cost of osteoporosis.

摘要

本研究的目的是根据绝经后骨质疏松症女性的SOTI和TROPOS临床试验结果,估算五个欧洲国家非椎体骨质疏松性骨折的单位成本。使用病例报告表中记录的信息。采用第三方支付方的视角。髋部骨折的单位成本最高。各国之间髋部骨折的成本范围较窄,从8346欧元(意大利)到9907欧元(法国),但其他骨折的成本范围较宽:腕部骨折从890欧元(西班牙)到2022欧元(意大利),骨盆骨折从1167欧元(西班牙)到3268欧元(意大利),胸骨/锁骨骨折从837欧元(西班牙)到2116欧元(意大利),肋骨骨折从565欧元(西班牙)到908欧元(法国),肱骨骨折从1518欧元(西班牙)到3651欧元(比利时),腿部骨折从1805欧元(西班牙)到3521欧元(意大利)。在估算骨质疏松症的成本时,应考虑这些骨折的成本。

相似文献

1
Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries.五个欧洲国家非椎体骨质疏松性骨折相关直接单位成本的估算。
Rheumatol Int. 2006 Oct;26(12):1063-72. doi: 10.1007/s00296-006-0180-x. Epub 2006 Sep 5.
2
Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.阿仑膦酸钠治疗9个欧洲国家绝经后妇女的成本效益——基于骨折干预试验的经济学评估
Osteoporos Int. 2007 Aug;18(8):1047-61. doi: 10.1007/s00198-007-0349-5. Epub 2007 Feb 28.
3
Non-hip peripheral osteoporotic fractures: epidemiology and significance.非髋部外周骨质疏松性骨折:流行病学及意义
Arh Hig Rada Toksikol. 2008 Mar;59(1):53-8. doi: 10.2478/10004-1254-59-2008-1850.
4
An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials.瑞典环境下雷奈酸锶治疗骨质疏松症的经济学评估:基于SOTI和TROPOS试验结果
Osteoporos Int. 2006 Dec;17(12):1781-93. doi: 10.1007/s00198-006-0193-z. Epub 2006 Sep 29.
5
Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.口服降糖药治疗的 2 型糖尿病患者的自我血糖监测(SMBG):法国、德国、意大利和西班牙的成本效益。
Curr Med Res Opin. 2010 Jan;26(1):163-75. doi: 10.1185/03007990903429765.
6
Acute coronary syndromes in Europe: 1-year costs and outcomes.欧洲急性冠状动脉综合征:1年的成本与结局
Curr Med Res Opin. 2007 Mar;23(3):495-503. doi: 10.1185/030079906X167462.
7
The mortality and direct medical costs of osteoporotic fractures among postmenopausal women in Taiwan.台湾绝经后妇女骨质疏松性骨折的死亡率及直接医疗费用。
Osteoporos Int. 2016 Feb;27(2):665-76. doi: 10.1007/s00198-015-3238-3. Epub 2015 Aug 5.
8
The burden-of-illness study on osteoporosis in the Slovenian female population.斯洛文尼亚女性人群骨质疏松症的疾病负担研究。
Pharm World Sci. 2007 Aug;29(4):404-11. doi: 10.1007/s11096-007-9091-5. Epub 2007 Feb 20.
9
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.利塞膦酸盐治疗骨质疏松症的成本效益:国际视角
Osteoporos Int. 2006;17(7):996-1007. doi: 10.1007/s00198-006-0094-1. Epub 2006 Mar 29.
10
Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database.2001年法国骨质疏松性骨折的发病率及费用。基于国家医院数据库的一种方法学途径。
Osteoporos Int. 2005 Dec;16(12):1475-80. doi: 10.1007/s00198-005-2031-0. Epub 2005 Oct 11.

引用本文的文献

1
An observational study of the radiofrequency echographic multi-spectrometry (REMS)-based fragility score of the lumbar spine and total fracture risk at 5 years in women.一项基于射频超声多谱学(REMS)的腰椎脆弱性评分及女性 5 年内总体骨折风险的观察性研究。
Rheumatol Int. 2023 Nov;43(11):2107-2114. doi: 10.1007/s00296-023-05412-4. Epub 2023 Aug 12.
2
Cost-DALY comparison of hip replacement care in 12 Belgian hospitals.12 家比利时医院髋关节置换护理的成本-生命年损失比较。
BMJ Open Qual. 2021 Sep;10(3). doi: 10.1136/bmjoq-2020-001263.
3
Updated incidence and costs of hip fractures in elderly Italian population.

本文引用的文献

1
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.雷奈酸锶降低绝经后骨质疏松症女性非椎体骨折风险:外周骨质疏松症治疗(TROPOS)研究。
J Clin Endocrinol Metab. 2005 May;90(5):2816-22. doi: 10.1210/jc.2004-1774. Epub 2005 Feb 22.
2
Epidemiology of osteoporotic fractures.骨质疏松性骨折的流行病学
Osteoporos Int. 2005 Mar;16 Suppl 2:S3-7. doi: 10.1007/s00198-004-1702-6. Epub 2004 Sep 8.
3
Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
意大利老年人群髋部骨折的更新发病率和成本。
Aging Clin Exp Res. 2020 Dec;32(12):2587-2593. doi: 10.1007/s40520-020-01497-0. Epub 2020 Feb 13.
4
Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.法国用于治疗绝经后骨质疏松症的雷奈酸锶片的成本效益分析。
Osteoporos Int. 2019 Mar;30(3):649-658. doi: 10.1007/s00198-018-04821-7. Epub 2019 Jan 30.
5
Activities of Daily Living and Determinant Factors among Older Adult Subjects with Lower Body Fracture after Discharge from Hospital: A Prospective Study.日常生活活动及老年下肢骨折患者出院后相关决定因素:一项前瞻性研究。
Int J Environ Res Public Health. 2018 May 16;15(5):1002. doi: 10.3390/ijerph15051002.
6
Healthcare Costs of Osteoporotic Fracture in Korea: Information from the National Health Insurance Claims Database, 2008-2011.韩国骨质疏松性骨折的医疗费用:来自国家健康保险理赔数据库的信息,2008 - 2011年
J Bone Metab. 2017 May;24(2):125-133. doi: 10.11005/jbm.2017.24.2.125. Epub 2017 May 31.
7
Public health impact and economic evaluation of vitamin D-fortified dairy products for fracture prevention in France.法国维生素D强化乳制品预防骨折的公共卫生影响及经济评估
Osteoporos Int. 2017 Mar;28(3):833-840. doi: 10.1007/s00198-016-3786-1. Epub 2016 Oct 18.
8
Burden of First Osteoporotic Hip Fracture in Spain: A Prospective, 12-Month, Observational Study.西班牙首次骨质疏松性髋部骨折的负担:一项前瞻性、为期12个月的观察性研究。
Calcif Tissue Int. 2017 Jan;100(1):29-39. doi: 10.1007/s00223-016-0193-8. Epub 2016 Oct 14.
9
Bone care nurses and the evolution of the nurse's educational function: the Guardian Angel(®) research project.骨护理护士与护士教育功能的演变:守护天使(®)研究项目
Clin Cases Miner Bone Metab. 2015 Jan-Apr;12(1):43-6. doi: 10.11138/ccmbm/2015.12.1.043.
10
A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality.骨质疏松性骨折患者出院后结局的系统评价:发病率、后续骨折和死亡率。
Ther Clin Risk Manag. 2014 Nov 18;10:937-48. doi: 10.2147/TCRM.S72456. eCollection 2014.
利塞膦酸盐治疗骨质疏松症的药物经济学分析
Int J Clin Pharmacol Res. 2003;23(4):93-105.
4
Strontium ranelate: a new paradigm in the treatment of osteoporosis.雷奈酸锶:骨质疏松症治疗的新范例。
Expert Opin Investig Drugs. 2004 Jul;13(7):857-64. doi: 10.1517/13543784.13.7.857.
5
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.雷奈酸锶对绝经后骨质疏松症女性椎体骨折风险的影响。
N Engl J Med. 2004 Jan 29;350(5):459-68. doi: 10.1056/NEJMoa022436.
6
Cost analysis of hip fracture treatment among the elderly for the public health services: a 1-year prospective study in 106 consecutive patients.公共卫生服务中老年人髋部骨折治疗的成本分析:对106例连续患者的1年前瞻性研究。
Arch Orthop Trauma Surg. 2003 Dec;123(10):551-4. doi: 10.1007/s00402-003-0583-z. Epub 2003 Sep 12.
7
Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis.雷奈酸锶治疗绝经后骨质疏松症女性临床开发的3期试验设计与方法
Osteoporos Int. 2003;14 Suppl 3:S66-76. doi: 10.1007/s00198-002-1341-8. Epub 2003 Mar 12.
8
Treatment of established osteoporosis: a systematic review and cost-utility analysis.已确诊骨质疏松症的治疗:一项系统评价与成本效益分析。
Health Technol Assess. 2002;6(29):1-146. doi: 10.3310/hta6290.
9
Direct medical costs attributable to osteoporotic fractures.骨质疏松性骨折所致的直接医疗费用。
Osteoporos Int. 2002;13(4):323-30. doi: 10.1007/s001980200033.
10
Incidence and costs of osteoporosis-associated hip fractures in Austria.奥地利骨质疏松症相关髋部骨折的发病率及费用
Wien Klin Wochenschr. 2001 May 15;113(10):371-7.